Date:6/9/2011

and economic conditions; and other factors beyond the companies' control and the risk factors and other cautionary statements described in Accuray's and TomoTherapy's filings with the SEC.  Please refer to the Risk Factors section of Accuray's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, the Risk Factors set forth in TomoTherapy's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as amended, and as updated in TomoTherapy's Form 10-Q for the fiscal quarter ended March 31, 2011, and the Risk Factors set forth in Accuray's Registration Statement on Form S-4, filed with the SEC on April 7, 2011 and as amended on May 5, 2011 and May 9, 2011, for a further list and description of additional business risks, uncertainties, and other factors that may affect these statements.  Neither Accuray nor TomoTherapy intends to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Important Additional Information

This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to purchase, shares of common stock of Accuray, nor does it constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of TomoTherapy.  In connection with the proposed merger, Accuray and TomoTherapy filed a definitive proxy statement/prospectus with the SEC on May 9, 2011.  This press release is not a substitute for the definitive proxy statement/prospectus. The definitive proxy statement of TomoTherapy and the prospectus of Accuray was mailed to the shareholders of TomoTherapy beginning on or about May 9, 2011.  BEFORE MAKING ANY INVESTMENT DECISION WITH RESPECT TO THE TRANSACTION, INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, REGISTRATION STATEMENT AND THE OTHER RELEVANT MATERIALS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABO
'/>"/>

SOURCE Accuray Incorporated Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Accuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
2. Accuray to Acquire TomoTherapy for Approximately $277 Million in Cash and Stock
3. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
4. Medco Chairman and CEO David Snow Addresses Shareholders, Highlighting Another Year of Growth, Innovation and Substantial Client Savings - With More to Come
5. Advanced Life Sciences Cancels Annual Meeting of Shareholders
6. Medco Announces Webcast for Annual Meeting of Shareholders
7. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
8. Johnson & Johnson Holds 2011 Annual Meeting of Shareholders
9. Dramatic Price Increases in Brand Name Drugs Spur Shareholders to Action
10. Shareholders to Challenge Johnson & Johnsons Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firms Failure to Disclose Financial Information on Firms ObamaCare Lobbying It Pledged to Release Last Year
11. Unilife Announces Chairmans Letter to Shareholders